Your browser doesn't support javascript.
loading
Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
Massafra, Vittoria; Tundo, Sofia; Dietzig, Aline; Ducret, Axel; Jost, Christian; Klein, Christian; Kontermann, Roland E; Knoetgen, Hendrik; Steegmaier, Martin; Romagnani, Andrea; Nagel, Yvonne A.
Afiliación
  • Massafra V; Molecular Targeted Therapy-Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Tundo S; Molecular Targeted Therapy-Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Dietzig A; Molecular Targeted Therapy-Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Ducret A; Pharmaceutical Sciences-Biomarkers, Bioinformatics, and Omics, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Jost C; Cancer Immunotherapy-Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Zurich, F. Hoffmann-La Roche Ltd., Schlieren, Switzerland.
  • Klein C; Cancer Immunotherapy-Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Zurich, F. Hoffmann-La Roche Ltd., Schlieren, Switzerland.
  • Kontermann RE; Institute of Cell Biology and Immunology, Stuttgart University, Stuttgart, Germany.
  • Knoetgen H; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and.
  • Steegmaier M; Large Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd., Penzberg, Germany.
  • Romagnani A; Molecular Targeted Therapy-Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Nagel YA; Molecular Targeted Therapy-Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland; yvonne_alice.nagel@roche.com.
J Immunol ; 207(2): 493-504, 2021 07 15.
Article en En | MEDLINE | ID: mdl-34215653
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Activación de Linfocitos / Antígenos de Histocompatibilidad Clase I / Quimera / Presentación de Antígeno / Anticuerpos Biespecíficos / Linfocitos T CD8-positivos / Neoplasias Límite: Humans Idioma: En Revista: J Immunol Año: 2021 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Activación de Linfocitos / Antígenos de Histocompatibilidad Clase I / Quimera / Presentación de Antígeno / Anticuerpos Biespecíficos / Linfocitos T CD8-positivos / Neoplasias Límite: Humans Idioma: En Revista: J Immunol Año: 2021 Tipo del documento: Article País de afiliación: Suiza